Literature DB >> 33432241

Reverse engineering Lewy bodies: how far have we come and how far can we go?

Mohamed Bilal Fares1,2, Somanath Jagannath3, Hilal A Lashuel4,5.   

Abstract

Lewy bodies (LBs) are α-synuclein (α-syn)-rich intracellular inclusions that are an important pathological hallmark of Parkinson disease and several other neurodegenerative diseases. Increasing evidence suggests that the aggregation of α-syn has a central role in LB formation and is one of the key processes that drive neurodegeneration and pathology progression in Parkinson disease. However, little is known about the mechanisms underlying the formation of LBs, their biochemical composition and ultrastructural properties, how they evolve and spread with disease progression, and their role in neurodegeneration. In this Review, we discuss current knowledge of α-syn pathology, including the biochemical, structural and morphological features of LBs observed in different brain regions. We also review the most used cellular and animal models of α-syn aggregation and pathology spreading in relation to the extent to which they reproduce key features of authentic LBs. Finally, we provide important insights into molecular and cellular determinants of LB formation and spreading, and highlight the critical need for more detailed and systematic characterization of α-syn pathology, at both the biochemical and structural levels. This would advance our understanding of Parkinson disease and other neurodegenerative diseases and allow the development of more-reliable disease models and novel effective therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33432241     DOI: 10.1038/s41583-020-00416-6

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  292 in total

Review 1.  Genetics of Parkinson's disease.

Authors:  Christine Klein; Ana Westenberger
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

3.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

4.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.

Authors:  Masato Hasegawa; Hideo Fujiwara; Takashi Nonaka; Koichi Wakabayashi; Hitoshi Takahashi; Virginia M-Y Lee; John Q Trojanowski; David Mann; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

5.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

6.  Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement.

Authors:  Andrés Binolfi; Rodolfo M Rasia; Carlos W Bertoncini; Marcelo Ceolin; Markus Zweckstetter; Christian Griesinger; Thomas M Jovin; Claudio O Fernández
Journal:  J Am Chem Soc       Date:  2006-08-02       Impact factor: 15.419

7.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

8.  Synthetic filaments assembled from C-terminally truncated alpha-synuclein.

Authors:  R A Crowther; R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1998-10-09       Impact factor: 4.124

9.  100 years of Lewy pathology.

Authors:  Michel Goedert; Maria Grazia Spillantini; Kelly Del Tredici; Heiko Braak
Journal:  Nat Rev Neurol       Date:  2012-11-27       Impact factor: 42.937

10.  N-alpha-acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation.

Authors:  Tim Bartels; Nora C Kim; Eric S Luth; Dennis J Selkoe
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

View more
  37 in total

1.  A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease.

Authors:  Morgan Bérard; Razan Sheta; Sarah Malvaut; Raquel Rodriguez-Aller; Maxime Teixeira; Walid Idi; Roxanne Turmel; Melanie Alpaugh; Marilyn Dubois; Manel Dahmene; Charleen Salesse; Jérôme Lamontagne-Proulx; Marie-Kim St-Pierre; Omid Tavassoly; Wen Luo; Esther Del Cid-Pellitero; Raza Qazi; Jae-Woong Jeong; Thomas M Durcan; Luc Vallières; Marie-Eve Tremblay; Denis Soulet; Martin Lévesque; Francesca Cicchetti; Edward A Fon; Armen Saghatelyan; Abid Oueslati
Journal:  PLoS Biol       Date:  2022-03-09       Impact factor: 8.029

2.  Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?

Authors:  Ivan A Kuznetsov; Andrey V Kuznetsov
Journal:  Math Biosci       Date:  2021-12-07       Impact factor: 2.144

3.  Roflupram protects against rotenone-induced neurotoxicity and facilitates α-synuclein degradation in Parkinson's disease models.

Authors:  Wen-Li Dong; Jia-Hong Zhong; Yun-Qing Chen; Jin-Feng Xie; Yun-Yun Qin; Jiang-Ping Xu; Ning-Bo Cai; Meng-Fan Li; Lu Liu; Hai-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2021-09-16       Impact factor: 6.150

Review 4.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

Review 5.  Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors:  Jia-Yi Li; Wen Li
Journal:  Front Cell Dev Biol       Date:  2021-05-13

Review 6.  Common Principles and Specific Mechanisms of Mitophagy from Yeast to Humans.

Authors:  Rajesh Kumar; Andreas S Reichert
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 7.  Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer's Disease.

Authors:  Makoto Hashimoto; Gilbert Ho; Shuei Sugama; Takato Takenouchi; Masaaki Waragai; Hiromu Sugino; Satoshi Inoue; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy.

Authors:  Nelson Ferreira; Mette Richner; Amelia van der Laan; Ida Bergholdt Jul Christiansen; Christian B Vægter; Jens R Nyengaard; Glenda M Halliday; Joachim Weiss; Benoit I Giasson; Ian R Mackenzie; Poul H Jensen; Asad Jan
Journal:  Brain Commun       Date:  2021-05-14

Review 9.  Proteolytic α-Synuclein Cleavage in Health and Disease.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan von Hörsten; Anja Schulze; Steffen Roßner
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

10.  α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response.

Authors:  Alberto Delaidelli; Mette Richner; Lixiang Jiang; Amelia van der Laan; Ida Bergholdt Jul Christiansen; Nelson Ferreira; Jens R Nyengaard; Christian B Vægter; Poul H Jensen; Ian R Mackenzie; Poul H Sorensen; Asad Jan
Journal:  Acta Neuropathol Commun       Date:  2021-06-06       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.